-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
The challenges of conducting clinical trials for neglected tropical diseases
Maria P Rebollo, Moses J Bockarie
Editorial: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Jeffrey A Cohen
Interview: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 7
Acknowledgements: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation